Patents Examined by Daniel E. Kolker
-
Patent number: 12258400Abstract: The present invention relates to antibodies having specificity for BTN2A and uses thereof, in particular for the treatment of cancer.Type: GrantFiled: March 20, 2020Date of Patent: March 25, 2025Assignees: IMCHECK THERAPEUTICS SAS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS—, INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITÉ D'AIX-MARSEILLEInventors: Etienne Foucher, Carla Cano, Kieu Suong Le, Christine Pasero, Daniel Olive
-
Patent number: 12259395Abstract: The present application provides methods, compositions and kits for determining SHD catabody levels in a biological sample, and for treating or preventing a protein aggregation disease (PAD) in an individual. Also provided are catabodies specifically recognizing amyloid beta (A?) peptides and methods of use thereof.Type: GrantFiled: August 16, 2019Date of Patent: March 25, 2025Assignee: AB Studio Inc.Inventor: Yue Liu
-
Patent number: 12246065Abstract: The invention provides a system that comprises pharmaceutical agents for use in immunotherapy for reducing the side-effects of an antigen-recognizing receptor against antigen-expressing non-target cells in an individual. The system includes an antigen-recognizing receptor that specifically recognizes an antigen on target cells and at least on one hematopoietic cell type in the individual. The antigen-recognizing receptor is exemplified by chimeric antigen receptors (CAR) be expressed on the surface of an immune effector cells. The system also includes hematopoietic cells resistant to recognition of the same antigen by the antigen-recognizing receptor.Type: GrantFiled: January 19, 2024Date of Patent: March 11, 2025Assignee: Miltenyi Biotec B.V. & Co. KgInventors: Michael Lutteropp, Anne Richter, Andrew Kaiser, Mario Assenmacher, Stefan Miltenyi
-
Patent number: 12247081Abstract: Provided are bispecific or multispecific antibodies that include an anti-CEACAM5 portion and one or more anti-4-1BB nanobodies whose agonist activity is dependent on the presence of the CEACAM5 antigen. Such bispecific or multispecific antibodies are safe, and are efficacious in treating cancer and have long-term protective immunological memory against tumors. Methods of using the antibodies for treating diseases such as cancer are also provided.Type: GrantFiled: May 8, 2024Date of Patent: March 11, 2025Assignee: LANOVA MEDICINES LIMITEDInventors: Runsheng Li, Wei Cao, Ying Qin Zang, Wentao Huang
-
Patent number: 12246058Abstract: The disclosure provides polypeptides and pharmaceutical compositions thereof. Such polypeptides can be useful, for example, in treating pain in a subject. In some embodiments, the polypeptides are useful for treating neuropathic and/or inflammatory pain.Type: GrantFiled: January 20, 2021Date of Patent: March 11, 2025Assignee: Creighton UniversityInventor: Shashank Dravid
-
Patent number: 12247073Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a CD33 polypeptide, e.g., a mammalian CD33 or human CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: August 30, 2019Date of Patent: March 11, 2025Assignee: ALECTOR LLCInventors: Patricia Culp, Helen Lam, Wei-Hsien Ho, Leonard G. Presta, Arnon Rosenthal
-
Patent number: 12247070Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat an atherosclerosis in a subject in need thereof.Type: GrantFiled: December 26, 2019Date of Patent: March 11, 2025Assignee: NEURACLE SCIENCE CO., LTD.Inventors: Bongcheol Kim, Dong Sik Kim, Jae-Keun Lee, Juwon Shim
-
Patent number: 12240904Abstract: The present disclosure provides the use of an anti-PD-1 antibody in combination with famitinib in the preparation of a drug for treating tumors. In the present technical solution, toxicity is controllable and tolerable. At the same time, the described drug combination effectively reduces adverse reactions to the anti-PD-1 antibody, such as the occurrence of reactive capillary endothelial proliferation.Type: GrantFiled: November 5, 2019Date of Patent: March 4, 2025Assignees: Jiangsu Hengrui Medicine Co., Ltd., Suzhou Suncadia Biopharmaceuticals Co., Ltd.Inventors: Lianshan Zhang, Qing Yang, Quanren Wang, Xiaoxing Huang, Cheng Liao, Changyong Yang, Dingwei Ye, Xiaohua Wu
-
Patent number: 12240912Abstract: Single domain antibodies are provided, which are capable of specifically binding to an epitope of a human complement factor selected from the group consisting of C1q, C3, C4 and/or the proteolytic derivatives C3b and C4b. Further the use of the antibodies are provided for methods in modulating the activity of the complement system as well as methods of treating disorders associated with complement activation.Type: GrantFiled: March 27, 2024Date of Patent: March 4, 2025Assignee: Aarhus UniversitetInventors: Nick Stub Laursen, Dennis Vestergaard Pedersen, Gregers Rom Andersen, Steffen Thiel, Alessandra Zarantonello, Rasmus Kjeldsen Jensen, Henrik Pedersen
-
Patent number: 12227572Abstract: The invention relates to a monoclonal humanized antibody or antigen-binding fragment thereof that specifically bind to the TRBV9 family of the human T cell receptor. The invention also relates to a nucleic acid encoding said antibody or antigen-binding fragment thereof, an expression vector, a method for preparing said antibody, and use of said antibody in treatment of diseases or disorders associated with the human T cell receptor family. The invention is directed to generation of antibodies that can be used for treating, in particular AS, celiac disease and malignant blood diseases, the pathogenesis of which involves the TRBV9 family TCRs.Type: GrantFiled: February 20, 2020Date of Patent: February 18, 2025Inventors: Olga Vladimirovna Britanova, Dmitry Borisovich Staroverov, Anna Valentinovna Evstrateva, Alexey Konstantinovich Misorin, Timofey Aleksandrovich Nemankin, Mariia Aleksandrovna Shchemeleva, Anna Konstantinovna Vladimirova, Arina Vitalevna Anikina, Roman Alekseevich Ivanov, Dmitry Valentinovich Morozov, Pavel Andreevich Iakovlev, Sergey Anatolievich Lukyanov
-
Patent number: 12227583Abstract: The present invention provides an anti-ox40 antibody, an antigen-binding fragment thereof, and the pharmaceutical use. Further, the present application provides a chimeric antibody and a humanized antibody, the chimeric antibody and the humanized antibody comprising a CDR region from the anti-OX40 antibody and the antigen-binding fragment thereof, and also provides a pharmaceutical composition comprising the anti-OX40 antibody and the antigen-binding fragment thereof, and the use thereof as a drug for treating cancers.Type: GrantFiled: September 25, 2019Date of Patent: February 18, 2025Assignee: Jiangsu Hengrui Medicine Co., Ltd.Inventors: Cheng Liao, Zupeng Xu, Jiahua Jiang, Xin Ye, Lianshan Zhang
-
Patent number: 12209133Abstract: The present invention relates to an isolated antibody which specifically binds human CD137, and pharmaceutical compositions and methods of use thereof. The present invention further relates to a nucleic acid comprising a nucleotide sequence encoding said antibody, a vector comprising said nucleic acid, a host cell comprising said nucleic acid or said vector, and a method of producing said antibody.Type: GrantFiled: October 9, 2019Date of Patent: January 28, 2025Assignee: Numab Therapeutics AGInventors: Tea Gunde, Matthias Brock, Christian Hess, Alexandre Simonin, Stefan Warmuth
-
Patent number: 12202877Abstract: The present disclosure provides methods for generating MAGE-B2 specific T cells and compositions comprising engineered MAGE-B2-specific T cell receptors. Further provided are methods of treating cancer comprising administering the MAGE-B2-specific T cells.Type: GrantFiled: April 19, 2019Date of Patent: January 21, 2025Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Cassian Yee, Ke Pan
-
Patent number: 12195538Abstract: The present disclosure provides an anti-PD-L1/anti-4-1BB bispecific antibody capable to effectively block the interactions between PD-L1 and its receptor PD-1 and between 4-1BB and its ligand. The bispecific antibody may have high binding affinity to both of a PD-L1 protein and a 4-1BB protein.Type: GrantFiled: February 15, 2019Date of Patent: January 14, 2025Assignees: ABL BIO INC., I-MAB BIOPHARMA US LIMITEDInventors: Eunyoung Park, Yangsoon Lee, Hyejin Chung, Eunsil Sung, Jiseon Yoo, Minji Park, Yong-Gyu Son, Hyoju Choi, Eunjung Kim, Jaeho Jung, Weon-Kyoo You, Sang Hoon Lee, Lei Fang, Wenqing Jiang
-
Patent number: 12193996Abstract: Described herein are compositions comprising subsets of monocyte having distinct functional properties and methods for using the same to treat infectious disease.Type: GrantFiled: November 12, 2021Date of Patent: January 14, 2025Assignees: The General Hospital Corporation, President and Fellows of Harvard CollegeInventors: Catherine Rhee, David T. Scadden
-
Patent number: 12195543Abstract: The present invention provides novel human fins related tyrosine kinase 3 (FLT3) antigen binding proteins, such as antibodies, having improved FLT3 binding affinity, and/or anti-tumor activity. The FLT3 antibodies of the invention were generated by mutation of a parent FLT3 antibody and tested in in vitro in binding assays as well as in vivo in a mouse tumor model and in human patient tumor samples. The antibodies of the invention are provided as monospecific constructs or in a bispecific FLT3×CD3 antibody format and show excellent target affinity and/or tumor cell killing. The present invention also relates methods for producing the antigen binding proteins of the invention as well as nucleic acids encoding them, vectors for and host cells for their expression. The invention further relates to methods of treating or diagnosing a disease such as leukemia using an FLT3 antigen binding protein (ABP) of the invention.Type: GrantFiled: September 11, 2019Date of Patent: January 14, 2025Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS, EBERHARD KARLS UNIVERSITAT TUBINGENInventors: Gundram Jung, Helmut Salih, Fabian Vogt, Latifa Zekri-Metref, Martin Pflügler, Isabelle Ehnes
-
Patent number: 12195546Abstract: Provided herein are multispecific binding proteins comprising (a) a first antigen binding domain (ABD) comprising an immunoglobulin single variable domain (ISVD) (e.g., VHH) with binding specificity to CD28; and (b) a second ABD comprising an immunoglobulin heavy chain variable domain (VH) and an immunoglobulin light chain variable domain (VL) with binding specificity to OX40. Also provided are methods of treating autoimmune diseases with said multispecific binding proteins.Type: GrantFiled: December 18, 2023Date of Patent: January 14, 2025Assignee: SANOFIInventors: Gerald Beste, Yanik Bruynooghe, Klervi Desrumeaux, Jennifer Kuehn, Charlotte Lahoute, Rami Lissilaa, Alessandro Masiero, Sevim Oezguer Bruederle, Benjamin Suratt, Emmanuelle Vigne, Jessica Voss
-
Patent number: 12187802Abstract: The present invention provides antibodies that bind to the IL-3 receptor alpha subunit alpha (Il3R?) chain, and compositions comprising such antibodies. The present invention provides methods for inhibiting or reducing an IL3R?-expressing cell population, the methods comprising contacting a population of IL3R?-expressing cells (e.g., cancer cells and/or cancer stem cells) with an antibody that binds to IL3R?. The present invention also provides antibody conjugates comprising an antibody that binds to an IL3R? chain linked to a cytotoxic agent or anticellular agent and compositions comprising such conjugates. The present invention also provides methods for preventing, treating and/or managing a disorder associated with IL3R?-expressing cells (e.g., a hematological cancer), the methods comprising administering to a subject in need thereof an antibody that binds to IL3R?.Type: GrantFiled: December 23, 2020Date of Patent: January 7, 2025Assignee: Stemline Therapeutics, Inc.Inventor: Ivan Bergstein
-
Patent number: 12173075Abstract: The present disclosure relates to biotechnology and provides antibodies that specifically bind to IL-5R?. The disclosure also relates to DNA encoding the antibodies, the corresponding expression vectors and methods of production thereof, as well as methods of treatment using the antibodies.Type: GrantFiled: October 2, 2018Date of Patent: December 24, 2024Inventors: Ekaterina Vladimirovna Sofronova, Aleksei Konstantinovich Misorin, Aleksandr Nikolaevich Doronin, Timofey Aleksandrovich Nemankin, Aleksandra Aleksandrovna Sozonova, Galina Stepanovna Zhirivskaia, Sergey Aleksandrovich Legotsky, Anna Konstantinovna Vladimirova, Alina Valerevna Beliasnikova, Mariia Aleksandrovna Shchemeleva, Pavel Andreevich Iakovlev, Valery Vladimirovich Solovyev, Elena Andreevna Krendeleva, Natalia Evgenevna Pestova, Dmitry Valentinovich Morozov
-
Patent number: 12173056Abstract: Disclosed is an isolated binding protein including a cardiac troponin I (cTnI) antigen binding domain, and preparation and a use and the like of the binding protein. The antigen binding domain includes at least one complementarity determining region selected from an amino acid sequence defined in this article, or has at least 80% sequence identity with the complementarity determining region of the amino acid sequence and has KD?9.96×10?8 mol/L affinity with cTnI. The binding protein may be used in the detection field of the cTnI protein.Type: GrantFiled: September 27, 2019Date of Patent: December 24, 2024Assignee: FAPON BIOTECH INC.Inventors: Peng Cui, Zhiqiang He, Yuan Meng, Dongmei Zhong